Cyanocapture
Photosynthetic biomanufacturing platform producing high-value molecules from CO2 for industrial and life-sciences customers
Highlights
- New on EvolcAdded 2026-11-12
About Cyanocapture
CyanoCapture develops photosynthetic biomanufacturing technology that uses engineered cells to produce molecules from CO2, including enzymes, peptides, growth factors, cytokines and commodity chemicals. Its platform also includes protein-shell nanocages for targeted drug delivery.
The company is based at Oxford Science Park in the UK. Its stated applications include industrial enzymes, bioplastics, serum-free media and therapeutic delivery.
Product: Engineered photosynthetic cell platform for producing high-value molecules from CO2, plus protein-shell nanocages for targeted drug delivery.
Jobs at Cyanocapture
More biotech & pharma companies
Cycle Pharmaceuticals
Rare disease medicines and patient support programmes for oncology, neurology, metabolic and immunology conditionsRemote-friendlyCyden
Manufacturer of energy-based at-home skin and hair devices for consumer and professional beauty marketsDaltontx
AI drug discovery platform for pharmaceutical, biotech and CRO discovery teamsYoung companyNew on EvolcDaresbury Proteins
Mammalian recombinant protein production and cell line development for academic and industry research partnersNew on EvolcDawn Therapeutics
Develops genetic medicine delivery platforms and a preclinical Hurler syndrome treatment for patients with serious diseasesNew on EvolcDloc Biosystems
Organ-on-chip systems and preclinical drug-testing services for pharmaceutical and biomedical research teamsYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.